# T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.

> **NCT02849886** · PHASE1,PHASE2 · TERMINATED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 2 (actual)

## Conditions studied

- Graft Versus Host Disease
- Hematological Malignancies

## Interventions

- **DRUG:** T lymphocytes iCASP9 ΔCD19
- **DRUG:** Dimerizer drug AP1903

## Key facts

- **NCT ID:** NCT02849886
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-10
- **Primary completion:** 2021-12-26
- **Final completion:** 2021-12-26
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** not enough recruitment because of new therapeutic alternatives
- **Last updated:** 2025-07-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02849886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02849886, "T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02849886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*